Savara, Inc. (SVRA)

Savara's stock has been impacted by several events. H.C. Wainwright upgraded Savara due to the potential refiling of its marketing application. Strong efficacy data from the Phase 3 IMPALA-2 trial for Molbreevi was published in the New England Journal of Medicine. Savara priced a $130 million equity offering at $4.20 per share, strengthening its balance sheet. The company reported a net loss of $29.6 million in Q3 2025, an increase from $24.2 million in Q3 2024. Savara resubmitted the Biologics License Application (BLA) for MOLBREEVI to the FDA and requested Priority Review. There was speculation regarding a potential takeover of Savara Inc. The company expects to submit Marketing Authorization Applications (MAA) for MOLBREEVI to the EMA and the MHRA in Q1 2026. A sell signal was issued on December 11, 2025, after which the stock fell by 23.58%.

As a clinical-stage biopharmaceutical company without commercialized products, Savara, Inc. does not experience traditional demand seasonality. Its financial performance is driven by clinical trial progress, regulatory milestones, and funding. Anticipated demand for MOLBREEVI upon potential market approval is expected to be high due to the unmet medical need in the autoimmune PAP patient population.

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Their lead product candidate, molgramostim (MOLBREEVI), is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no approved pharmacologic treatments in the U.S. or Europe. The company aims to gain regulatory approval and commercialize MOLBREEVI as the first treatment for aPAP. Another product, AeroVanc, has completed Phase 3 development but is currently considered a non-core asset.

Savara, Inc. is headquartered in Langhorne, Pennsylvania, with initial operations in Austin, Texas. The company is seeking regulatory approval and commercialization for MOLBREEVI in the United States and Europe.

Savara Inc.'s brand reputation has been positively influenced by the progress of MOLBREEVI, particularly the publication of strong efficacy data from the Phase 3 IMPALA-2 trial. The company's focus on addressing an unmet medical need in a rare disease contributes to a favorable reputation. However, a Refuse to File (RTF) letter from the FDA due to CMC issues temporarily impacted its reputation, though the company has addressed these concerns. Ongoing net losses are also a consideration for investors.

Savara Inc.'s ownership is predominantly held by institutional investors, accounting for approximately 87.93% of the shares, while insider ownership stands at about 5.38%. Major institutional shareholders include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, VR Adviser, LLC, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., Vanguard Group Inc, Nantahala Capital Management, LLC, BlackRock, Inc., Deerfield Management Company, L.p. (series C), and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares.